1
|
Najjar R, Paver E, McGuane J, Frahm‐Jensen G. Dissecting a diagnostic enigma: Hypertension in a young patient from an organ of Zuckerkandl paraganglioma. Clin Case Rep 2023; 11:e8061. [PMID: 37854255 PMCID: PMC10580690 DOI: 10.1002/ccr3.8061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 09/17/2023] [Accepted: 09/27/2023] [Indexed: 10/20/2023] Open
Abstract
Hypertension in young patients can mask rare conditions like paragangliomas, especially in the absence of conventional symptoms. A comprehensive diagnostic evaluation and multidisciplinary approach are crucial for optimal management and outcomes.
Collapse
Affiliation(s)
- Reabal Najjar
- The Australian National University Medical School, College of Health and Medicine, Australian Capital TerritoryCanberraAustralian Capital TerritoryAustralia
- The Canberra Hospital, Canberra Health ServicesCanberraAustralian Capital TerritoryAustralia
| | - Elizabeth Paver
- The Australian National University Medical School, College of Health and Medicine, Australian Capital TerritoryCanberraAustralian Capital TerritoryAustralia
- ACT Pathology, The Canberra HospitalCanberraAustralian Capital TerritoryAustralia
| | - Jonathan McGuane
- The Australian National University Medical School, College of Health and Medicine, Australian Capital TerritoryCanberraAustralian Capital TerritoryAustralia
- ACT Pathology, The Canberra HospitalCanberraAustralian Capital TerritoryAustralia
| | - Gert Frahm‐Jensen
- Department of Vascular SurgeryThe Canberra HospitalCanberraAustralian Capital TerritoryAustralia
| |
Collapse
|
2
|
Paver E, Aivazian K, Maclean F, Long GV, Spillane AJ, Wilmott JS, Scolyer RA. Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. Pathology 2022; 55:555-560. [PMID: 36400594 DOI: 10.1016/j.pathol.2022.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 08/19/2022] [Accepted: 08/22/2022] [Indexed: 11/17/2022]
|
3
|
Ho G, Schwartz RJ, Regio Pereira A, Dimitrou F, Paver E, McKenzie C, Saw RPM, Scolyer RA, Long GV, Guitera P. Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. J Eur Acad Dermatol Venereol 2022; 36:e583-e585. [PMID: 35285090 DOI: 10.1111/jdv.18076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 03/04/2022] [Indexed: 11/27/2022]
Affiliation(s)
- G Ho
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - R J Schwartz
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Department of Dermatology, Faculty of Medicine, University of Chile, Santiago, Chile
| | - A Regio Pereira
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - F Dimitrou
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - E Paver
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- NSW Health Pathology, Sydney, New South Wales, Australia
| | - C McKenzie
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- NSW Health Pathology, Sydney, New South Wales, Australia
| | - R P M Saw
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - R A Scolyer
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- NSW Health Pathology, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
| | - G V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- Royal North Shore Hospital and Mater Hospitals, Sydney, New South Wales, Australia
| | - P Guitera
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
4
|
Zilberg C, Paver E, Damian D. Rapid Development of Syringocystadenocarcinoma Papilliferum in an Immunosuppressed Liver Transplant Recipient. Case Rep Dermatol 2022; 14:127-131. [PMID: 35813836 PMCID: PMC9209998 DOI: 10.1159/000524821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 04/24/2022] [Indexed: 11/19/2022] Open
Abstract
Syringocystadenocarcinoma papilliferum (SCACP) is a rare cutaneous adnexal neoplasm. To the best of our knowledge, fewer than 50 cases have been described in the literature. We describe the first reported case of an SCACP in an immunocompromised patient. We report the development of an SCACP over 3 months in a 77-year-old organ transplant recipient undergoing regular dermatological follow-up. The lesion was excised with clear margins with Mohs micrographic surgery. This lesion's rapid development and small size contrasts with the predominantly slow-growing, larger lesions described in immunocompetent patients. Lastly, this case further highlights the importance of close dermatological follow-up of immunosuppressed patients.
Collapse
Affiliation(s)
- Catherine Zilberg
- Dermatology, The University of Sydney at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- *Catherine Zilberg,
| | - Elizabeth Paver
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Melanoma Institute Australia, Sydney, New South Wales, Australia
| | - Diona Damian
- Dermatology, The University of Sydney at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Melanoma Institute Australia, Sydney, New South Wales, Australia
| |
Collapse
|
5
|
Schwartz RJ, Ho G, Smith A, Collgros H, Regio Pereira A, Gouveia B, Long GV, Menzies AM, Potter AJ, Paver E, Star P, Scolyer RA, Martin LK. Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy. J Eur Acad Dermatol Venereol 2022; 36:e445-e448. [PMID: 35043483 DOI: 10.1111/jdv.17940] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 01/05/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Rodrigo J Schwartz
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Department of Dermatology, Faculty of Medicine, University of Chile, Santiago, Chile
| | - Genevieve Ho
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Annika Smith
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Helena Collgros
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, Australia
| | - Amanda Regio Pereira
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, Australia.,Federal University of Sao Paulo, Sao Paulo, Brazil
| | - Bruna Gouveia
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - Georgina V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Royal North Shore and Mater Hospitals, Sydney, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, Australia
| | - Alexander M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Royal North Shore and Mater Hospitals, Sydney, Australia
| | - Alison J Potter
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.,Tissue and Pathology Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia
| | - Elizabeth Paver
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Tissue and Pathology Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia
| | - Phoebe Star
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - Richard A Scolyer
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Tissue and Pathology Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, Australia
| | - Linda K Martin
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.,Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
| |
Collapse
|
6
|
Jiang X, Wen J, Paver E, Wu YH, Sun G, Bullman A, Dahlstrom JE, Tremethick DJ, Soboleva TA. H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma. EMBO Rep 2021; 22:e52462. [PMID: 34350706 DOI: 10.15252/embr.202152462] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 06/02/2021] [Accepted: 06/15/2021] [Indexed: 12/12/2022] Open
Abstract
Testis-specific regulators of chromatin function are commonly ectopically expressed in human cancers, but their roles are poorly understood. Examination of 81 primary Hodgkin lymphoma (HL) samples showed that the ectopic expression of the eutherian testis-specific histone variant H2A.B is an inherent feature of HL. In experiments using two HL cell lines derived from different subtypes of HL, H2A.B knockdown inhibited cell proliferation. H2A.B was enriched in both nucleoli of these HL cell lines and primary HL samples. We found that H2A.B enhanced ribosomal DNA (rDNA) transcription, was enriched at the rDNA promoter and transcribed regions, and interacted with RNA Pol I. Depletion of H2A.B caused the loss of RNA Pol I from rDNA chromatin. Remarkably, H2A.B was also required for high levels of ribosomal protein gene expression being located at the transcriptional start site and within the gene body. H2A.B knockdown reduced gene body chromatin accessibility of active RNA Pol II genes concurrent with a decrease in transcription. Taken together, our data show that in HL H2A.B has acquired a new function, the ability to increase ribosome biogenesis.
Collapse
Affiliation(s)
- Xuanzhao Jiang
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Jiayu Wen
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Elizabeth Paver
- Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
| | - Yu-Huan Wu
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Gege Sun
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Amanda Bullman
- Department of Anatomical Pathology, ACT Pathology, The Canberra Hospital, Canberra, ACT, Australia
| | - Jane E Dahlstrom
- Department of Anatomical Pathology, ACT Pathology, The Canberra Hospital, Canberra, ACT, Australia.,Australian National University Medical School, The Australian National University, Canberra, ACT, Australia
| | - David J Tremethick
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| | - Tatiana A Soboleva
- The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
| |
Collapse
|
7
|
Paver E, O'Toole S, Cheng XM, Mahar A, Cooper WA. Updates in the molecular pathology of non-small cell lung cancer. Semin Diagn Pathol 2021; 38:54-61. [PMID: 33985831 DOI: 10.1053/j.semdp.2021.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 04/04/2021] [Accepted: 04/08/2021] [Indexed: 12/21/2022]
Abstract
An understanding of the molecular pathology of non-small cell lung cancer (NSCLC) is important for pathologists as molecular characterization is now required for treatment decisions in advanced stage disease. While assessment for EGFR mutations, ALK and ROS1 fusions, and in some countries BRAF mutations, is now standard practice, other oncogenic mutations are also emerging that may impact routine clinical practice including alterations involving KRAS, NTRK, RET, MET and HER2. In addition, molecular pathology alterations of NSCLC are associated with responses to immune checkpoint therapy and are being increasingly investigated. Finally, specific molecular pathological alterations define some rarer subtypes of NSCLC such as salivary gland tumours, NUT carcinoma and SMARCA4-deficient undifferentiated tumour, and an understanding of the molecular pathology is important for their accurate diagnosis. In this review, the molecular pathology of NSCLC is discussed with a focus on clinically relevant molecular alterations.
Collapse
Affiliation(s)
- Elizabeth Paver
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
| | - Sandra O'Toole
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia
| | - Xin Min Cheng
- Department of Anatomical Pathology, Singapore General Hospital, Singapore
| | - Annabelle Mahar
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
| | - Wendy A Cooper
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia.
| |
Collapse
|
8
|
Mourad AP, De Robles MS, O'Toole S, Paver E, Winn RD. A case of an asymptomatic sacrococcygeal teratoma diagnosed in adulthood. J Surg Case Rep 2020; 2020:rjaa462. [PMID: 33294159 PMCID: PMC7700776 DOI: 10.1093/jscr/rjaa462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Accepted: 10/13/2020] [Indexed: 11/14/2022] Open
Abstract
Sacrococcygeal teratomas are rare congenital tumours that are even more uncommon when present in adulthood. They are derived from residual stem cells in the presacral space that differentiate into clusters of somatic cell. We present the diagnosis, management and post-operative follow-up in a 37-year-old gentleman referred to our department with an incidental finding of a lobulated presacral cystic mass on computed tomography imaging. Magnetic resonance imaging and fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans were performed to further characterize the lesion. The decision was then made for surgical excision and the specimen along with the coccyx was retrieved en-bloc via a trans-sacral surgical approach. Histopathology of the mass uncovered the presence of squamous, respiratory and prostatic epithelium consistent with the diagnosis of a sacrococcygeal teratoma.
Collapse
Affiliation(s)
- Ali P Mourad
- Department of Surgery, The Wollongong Hospital, Wollongong, New South Wales, Australia
| | | | - Sandra O'Toole
- Department of Tissue, Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Elizabeth Paver
- Department of Tissue, Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Robert D Winn
- Department of Surgery, The Wollongong Hospital, Wollongong, New South Wales, Australia
| |
Collapse
|
9
|
Hale S, Paver E, McCluggage W, Llewellyn H. 26. A rare case of inverted papilloma of the female lower genital tract, with positivity for human papilloma virus 42. Pathology 2020. [DOI: 10.1016/j.pathol.2020.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Paver E, Currie A, Jain S. You may not always get the gist...A case report. Pathology 2016. [DOI: 10.1016/j.pathol.2015.12.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Paver E, Bogun Y. Testicular pain with a twist – A case report. Pathology 2016. [DOI: 10.1016/j.pathol.2015.12.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|